Radiopharm Theranostics Limited

OTCPK:RDPT.F Stock Report

Market Cap: US$47.1m

Radiopharm Theranostics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:RDPT.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
16 Dec 24BuyUS$153,475Riccardo CanevariIndividual7,776,402US$0.02
05 Dec 24SellUS$27,711Paul HopperIndividual1,500,000US$0.018
18 Oct 24BuyUS$6,269Ian TurnerIndividual333,864US$0.019
13 Sep 24BuyUS$100,691Ian TurnerIndividual3,750,000US$0.027
13 Sep 24BuyUS$26,851Leila AllandIndividual1,000,000US$0.027
13 Sep 24BuyUS$100,691Riccardo CanevariIndividual3,750,000US$0.027
13 Sep 24BuyUS$26,045Phillip HainsIndividual970,000US$0.027
13 Sep 24BuyUS$14,768Hester LarkinIndividual550,000US$0.027
23 Aug 24SellUS$1,441,094UBS Asset Management AGCompany63,361,184US$0.023
22 Aug 24BuyUS$2,503UBS Asset Management AGCompany112,100US$0.022
21 Aug 24BuyUS$3,289,622UBS Asset Management AGCompany123,331,549US$0.027
21 Aug 24SellUS$229,297UBS Asset Management AGCompany9,243,991US$0.025
16 Aug 24BuyUS$4,853Regal Partners LimitedCompany203,105US$0.024
12 Aug 24SellUS$116,948Regal Partners LimitedCompany5,369,673US$0.023
01 Jul 24BuyUS$1,455,538JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany54,545,160US$0.033
01 Jul 24BuyUS$2,000,966Regal Partners LimitedCompany75,246,901US$0.027
01 Jul 24SellUS$13,261JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany499,889US$0.033
01 Jul 24BuyUS$15,878,900NanoMab Technology LimitedCompany597,130,727US$0.027

Insider Trading Volume

Insider Buying: RDPT.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of RDPT.F?
Owner TypeNumber of SharesOwnership Percentage
Private Companies69,975,6223.22%
Public Companies149,625,1806.89%
Hedge Funds160,080,3337.37%
Institutions233,185,06310.7%
Individual Insiders259,798,72712%
General Public1,300,295,83159.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 482.8%.

Top Shareholders

Top 25 shareholders own 40.15% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.17%
JPMorgan Chase & Co, Brokerage and Securities Investments
177,585,973US$3.8m0%no data
7.37%
Regal Partners Limited
160,080,333US$3.5m0%0.11%
6.89%
Lantheus Holdings, Inc.
149,625,180US$3.2m0%no data
6.8%
Paul Hopper
147,721,428US$3.2m-1.01%no data
2.35%
UBS Asset Management AG
51,127,261US$1.1m0%no data
1.99%
NanoMab Technology Limited
43,295,131US$937.7k53%no data
1.5%
Danny Segman
32,500,000US$703.9k306%no data
1.1%
Scarlett Hopper
23,857,142US$516.7k0%no data
0.97%
Riccardo Canevari
21,179,986US$458.7k58%no data
0.73%
Phillip Hains
15,956,632US$345.6k0%no data
0.73%
Shared Office Services Pty Ltd
15,839,358US$343.1k0%no data
0.23%
Ian Turner
4,955,292US$107.3k7.22%no data
0.21%
Su-Ming Wong
4,532,158US$98.2k0%no data
0.14%
Flocell Ab
3,123,880US$67.7k0%no data
0.14%
Jcr Investments Co
3,010,000US$65.2k0%no data
0.13%
Niv Dagan
2,900,862US$62.8k0%no data
0.12%
Mann Beef Pty Ltd
2,601,000US$56.3k0%no data
0.11%
Zerrin Investments Pty Ltd, Asset Management Arm
2,425,000US$52.5k0%5.95%
0.098%
Hsuan Tseng Tzu
2,121,829US$46.0k0%no data
0.097%
Humanndiagnostics GmbH
2,106,253US$45.6k0%no data
0.094%
Scintilla Capital Pty Ltd
2,046,829US$44.3k0%1.09%
0.057%
David Mozley
1,240,000US$26.9k0%no data
0.049%
Leila Alland
1,071,740US$23.2k0%no data
0.046%
Thomas Tulip
1,000,000US$21.7k0%no data
0.03%
Hester Larkin
644,247US$14.0k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 13:42
End of Day Share Price 2024/10/22 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Radiopharm Theranostics Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Justin WalshJonesTrading Institutional Services, LLC
null nullLodge Partners Pty Ltd.